Mirum Pharmaceuticals, Inc. (MIRM) Financial Statements (2024 and earlier)

Company Profile

Business Address 950 TOWER LANE, SUITE 1050
FOSTER CITY, CA 94404
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments329,954132,073151,719185,347124,953139,908
Cash and cash equivalents297,22849,41928,00335,75955,26846,272
Short-term investments32,72682,654123,716149,58869,68593,636
Receivables35,32624,66123,99416,33713,9907,872
Inventory, net of allowances, customer advances and progress billings8,5096,6135,5656,9434,5241,580
Inventory8,5096,6135,5656,9434,5241,580
Other undisclosed current assets9,7298,9878,9476,9293,7785,908
Total current assets:383,518172,334190,225215,556147,245155,268
Noncurrent Assets
Operating lease, right-of-use asset1,6141,2871,4311,2541,3621,468
Property, plant and equipment866877914795832898
Intangible assets, net (including goodwill)56,43757,69558,95445,03246,07218,481
Intangible assets, net (excluding goodwill)56,43757,69558,95445,03246,07218,481
Other noncurrent assets1,1531,3371,3821,7101,7222,033
Other undisclosed noncurrent assets  100,000100,000100,000100,000100,000
Total noncurrent assets:60,070161,196162,681148,791149,988122,880
TOTAL ASSETS:443,588333,530352,906364,347297,233278,148
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities57,13946,83962,70859,01749,48131,826
Employee-related liabilities10,1586,823
Accounts payable14,4466,4408,69010,5488,1194,943
Accrued liabilities42,69340,39954,01838,31134,53926,883
Derivative instruments and hedges, liabilities  1,0901,0901,7641,7641,996
Other undisclosed current liabilities1,064914931(9,383)(6,071)731
Total current liabilities:58,20348,84364,72951,39845,17434,553
Noncurrent Liabilities
Long-term debt and lease obligation305,611  1,3111,5171,713
Long-term debt, excluding current maturities305,611     
Liabilities, other than long-term debt1,1641,8275,7894,3244,13910
Other liabilities107724,5324,3244,13910
Operating lease, liability1,1541,0551,2571,3111,5171,713
Other undisclosed noncurrent liabilities  141,710140,351138,017135,716132,940
Total noncurrent liabilities:306,775143,537146,140143,652141,372134,663
Total liabilities:364,978192,380210,869195,050186,546169,216
Equity
Equity, attributable to parent78,610141,150142,037169,297110,687108,932
Common stock444433
Additional paid in capital575,522563,964535,074526,099431,573402,825
Accumulated other comprehensive income (loss)76136(217)(413)(202)(131)
Accumulated deficit(496,992)(422,954)(392,824)(356,393)(320,687)(293,765)
Total equity:78,610141,150142,037169,297110,687108,932
TOTAL LIABILITIES AND EQUITY:443,588333,530352,906364,347297,233278,148

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues37,49731,59827,90618,78017,48412,892
Gross profit:37,49731,59827,90618,78017,48412,892
Operating expenses(61,770)(58,746)(62,067)(51,662)(48,925)(45,628)
Operating loss:(24,273)(27,148)(34,161)(32,882)(31,441)(32,736)
Nonoperating income (expense)3,3531,4611,5551,1601,592(85)
Investment income, nonoperating3,6272,2722,1431,35229369
Other nonoperating income (expense)(274)(811)(588)(192)1,299(154)
Interest and debt expense (49,076)     
Loss from continuing operations before equity method investments, income taxes:(69,996)(25,687)(32,606)(31,722)(29,849)(32,821)
Other undisclosed loss from continuing operations before income taxes(3,726)(4,242)(3,685)(3,971)(3,643)(3,774)
Loss from continuing operations before income taxes:(73,722)(29,929)(36,291)(35,693)(33,492)(36,595)
Income tax expense (benefit)(316)(201)(140)(13)6,570(11)
Loss from continuing operations:(74,038)(30,130)(36,431)(35,706)(26,922)(36,606)
Loss before gain (loss) on sale of properties:(35,706)(26,922)(36,606)
Net loss available to common stockholders, basic:(74,038)(30,130)(36,431)(35,706)(26,922)(36,606)
Other undisclosed net loss available to common stockholders, diluted   (765) (199) 
Net loss available to common stockholders, diluted:(74,038)(30,130)(37,196)(35,706)(27,121)(36,606)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(74,038)(30,130)(36,431)(35,706)(26,922)(36,606)
Comprehensive loss:(74,038)(30,130)(36,431)(35,706)(26,922)(36,606)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(60)353196(211)(71)(96)
Comprehensive loss, net of tax, attributable to parent:(74,098)(29,777)(36,235)(35,917)(26,993)(36,702)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: